Arecor Therapeutics (STU:6UI) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6UI Arecor Therapeutics PLC STU:6UI
37 GF Score
Price €0.69
GF Value €0.49
! 6 Warning Signs
View Full Analysis

What is Arecor Therapeutics 5-Year Yield-on-Cost %?

Arecor Therapeutics STU:6UI -3.52% 37 5-Year Yield-on-Cost % is 0.00 as of Aug. 01, 2026. GuruFocus rates STU:6UI with a GF Score™ of 37/100 and a GF Value™ of €0.49. The stock has 6 warning signs investors should review. Among 150 Biotechnology companies, Arecor Therapeutics ranks worse than 666666% on this metric.

Arecor Therapeutics's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Arecor Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



STU:6UI's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.71
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Arecor Therapeutics  (STU:6UI) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Arecor Therapeutics 5-Year Yield-on-Cost % Related Terms


STU:6UI vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Arecor Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arecor Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Arecor Therapeutics's 5-Year Yield-on-Cost % falls into.


STU:6UI
37GF Score
Arecor Therapeutics PLC STU:6UI
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arecor Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Arecor Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Arecor Therapeutics (STU:6UI) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 01, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Arecor Therapeutics and its competitors. According to the industry distribution chart, Arecor Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry.
Is Arecor Therapeutics' 5-Year Yield-on-Cost % too high?
Arecor Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Arecor Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arecor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arecor Therapeutics ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places Arecor Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.71, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Arecor Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arecor Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (STU:6UI) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is €0.49, compared to a current price of €0.69 — trading 39.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Arecor Therapeutics' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Arecor Therapeutics (STU:6UI), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arecor Therapeutics (STU:6UI) Overvalued in 2026?

Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued. The current stock price of €0.69 is trading 39.8% above its estimated GF Value™ of €0.49.

Key valuation signals for STU:6UI:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: €0.49 vs. price of €0.69 (39.8% above fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the STU:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arecor Therapeutics Business Description

Other Exchanges AREC:UK
Address Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score

Get the complete analysis for STU:6UI

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.69
Price
€0.49
GF Value